Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DXR
DXR logo

DXR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Daxor Corp (DXR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
10.750
1 Day change
-4.87%
52 Week Range
14.760
Analysis Updated At
2026/05/15
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Daxor Corp (DXR) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some short-term technical strength, but there is no AI Stock Picker or SwingMax signal, no recent news catalyst, no meaningful analyst momentum, and no financial snapshot to support a confident long-term purchase. Since the user is impatient and does not want to wait for an ideal entry, I would still not recommend buying now; the better call is to hold and wait for clearer confirmation or better fundamental visibility.

Technical Analysis

DXR closed at 10.50 after a drop from 11.30, which is a near-term pullback despite the note that regular market change was 11.11%. Technically, momentum is mixed to mildly positive: MACD histogram is above zero and expanding, which supports bullish momentum, while RSI_6 at 67.287 is close to overbought territory and does not offer a clean entry signal. Moving averages are converging, suggesting the trend is still undecided rather than strongly trending. Price is trading near the pivot level of 10.546, with resistance at 11.738 and 12.474 and support at 9.354 and 8.618. The next-day and next-week pattern probabilities are positive, but this is not enough to override the lack of stronger signals.

Positive Catalysts

  • MACD is positive and expanding, suggesting improving momentum. Similar candlestick pattern analysis points to a 70% chance of upside over the next day, week, and month. The stock is near pivot support, which could provide a short-term technical base. No recent news means there is no obvious negative event pressure.

Neutral/Negative Catalysts

  • No news in the past week means there is no clear catalyst driving a new uptrend. Hedge funds are neutral and insiders are neutral, so there is no strong institutional or insider confidence signal. AI Stock Picker shows no signal and SwingMax shows no recent signal. RSI is elevated enough to reduce attractiveness for a fresh entry. Financial data is unavailable, so long-term fundamental support cannot be confirmed. No recent congress trading data is available.

Financial Performance

No usable latest quarter financial snapshot was provided, so there is no confirmed revenue, earnings, or growth trend to assess for the latest quarter season.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no recent Wall Street upgrade/downgrade trend to support a bullish or bearish consensus view. Based on the available information, Wall Street sentiment appears neutral rather than strongly constructive.

Wall Street analysts forecast DXR stock price to rise
Analyst Rating
0
Wall Street analysts forecast DXR stock price to rise
Buy
Hold
Sell
0
Current: 11.300
sliders
Low
0
Averages
0
High
0
0
Current: 11.300
sliders
Low
0
Averages
0
High
0
Lake Street
NULL -> Buy
initiated
$23
AI Analysis
2026-02-11
Reason
Lake Street
Price Target
$23
AI Analysis
2026-02-11
initiated
NULL -> Buy
Reason
Lake Street initiated coverage of Daxor with a Buy rating and $23 price target, calling it an "overlooked high-growth MedTech diagnostic company addressing a multi-billion-dollar" total addressable market focused on accurate blood volume analysis. The firm thinks the Street is missing the underlying fundamental strength of Daxor's operating business given Daxor's filing status as a 1940 Act Investment Fund, the analyst added.

People Also Watch